Elixinol Global Limited Annual Report 2020

Q1 FY2020 Elixinol Global announces a simplified business strategy to focus on hemp derived CBD products Successfully global relaunch of new Elixinol brand along with innovative new, consumer- led product range Q2 FY2020 Oliver Horn is appointed Non-Executive Board Director of Elixinol Global Chairman and Non-Executive Director Andrew Du¡ and Non-Executive Director Greg Ellery resign from the Board Stratos Karousos ceased as CEO and Oliver Horn is appointed Global CEO of Elixinol Global Helen Wiseman joins the Board as a Non-Executive Director Sales channels adapted in response to COVID-19 environment to service e-commerce and in-home shopping more extensively Elixinol-branded CBD nutraceuticals consumer strategy becomes key revenue channel focus, with a more focused branded business model geared towards margin accretion Focus on improving e-commerce platform with the introduction of Magento in order to become a digitally led consumer business in the US, Europe and UK Elixinol Global announces capital raise to support operating cash flow, consumer brand building and expand distribution Sale of the land owned by Nunyara Pharma Pty Ltd in order to redeploy the cash proceeds to support Elixinol’s branded CBD nutraceuticals strategy Completes capital raise, raising ~$11m with support from institutional and retail investors FY2020 Milestones F Y2020 MI LES TONES 8 Elixinol Global Limited | Annual Report 2020